Targovax ASA announces one-year data for modified cohort of TG01 trial.
M2 PHARMA-October 12, 2017-Targovax ASA announces one-year data for modified cohort of TG01 trial
(C)2017 M2 COMMUNICATIONS
Norwegian clinical stage company Targovax ASA (NO: TRVX) has announced one-year data on the survival rate, immune activation and safety in the modified cohort of the TG01 trial in resected pancreatic cancer patients, the company revealed on Thursday.
Targovax, which focuses on the development of immuno-oncology therapies to target solid tumours, said that its study was structured as an open label, phase I/II trial of TG01/GM-CSF in combination with gemcitabine as adjuvant therapy for treating patients with resected adenocarcinoma of the pancreas.
It was composed of two cohorts: the main group of 19 patients and a second, modified group of 13 patients. The results showed that 100% of patients (13/13) were alive one year after surgery, that TG01/GM-CSF generated an immune response in 85% of patients (11/13), and there were no serious adverse events related to allergic reactions.
Magnus Jaderberg MD, chief medical officer of Targovax, commented: "We are delighted that we maintain a strong immune response and one-year survival rate with the reduced dosing regimen, essentially equivalent to and consistent with the previously reported data from the main cohort.
"This further strengthens the safety profile of TG01, and adds valuable understanding that will help us optimise the dosing regimen in resected pancreatic cancer patients, a condition which is notoriously difficult to treat. We look forward to see the two-year survival data for the modified cohort next year."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 12, 2017|
|Previous Article:||Sanofi to expand vaccine manufacturing site in Val de Reuil, France.|
|Next Article:||Amerigen unveils generic bexarotene capsules for US market.|